Finzati - Logo
RPRX logo

Royalty Pharma plc

RPRX • Medical - Pharmaceuticals
$63.96
▲ +0.08 (+0.13%)
Current price
EarningsLatest report: Mar 31, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$35.79B
Growth
7.3%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 32.4%Positive free cash flow · 5.76Consistent free cash flow · 5/5Reasonable earnings multiple · 21.65Weak liquidity · 0.97
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 6, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:36 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$63.96
Change0.13%
Shares Out559.61M
Market Cap$35.79B
Enterprise Value$44.14B
52W Range34.08 - 56.50
Beta0.44
P/E43.25
P/S14.67
P/B5.20
P/FCF16.26
EV/Sales18.09

Investment DNA

How strong this company looks for long-term investors

75
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
53/100
Growth Potential
Revenue and expansion
43/100
Price Attractiveness
Cheap or expensive today
69/100
Why this score▼
Stable or improving margins · 32.4%Positive free cash flow · 5.76Consistent free cash flow · 5/5Reasonable earnings multiple · 21.65Weak liquidity · 0.97

Analyst view

Analyst sentiment and price target

RPRX
Analyst sentiment
Based on 11 analyst votes · 2026-09-05
100/100
Bullish
Bullish
11
Hold
0
Bearish
0
Price Target
2026-06-24
Low
$50.00
Mean
$56.67
Median
$57.00
High
$63.00

Company Overview

IPO: 6/16/2020
Industry: Medical - Pharmaceuticals
P/B i: 5.20
Debt / Equity i: 1.38
Operating Margin: 65.58%
Net Margin: 32.42%
ROE i: -
ROIC: -

Financial Health

Score11 / 20
Debt / Equity: 1.38
Current Ratio: 0.97
Quick Ratio: 0.97
Status: Moderate

Warnings

  • Weak Liquidity

Insider Transactions

Recent executive and insider activity

Bassler Bonnie L
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY
Coric Vlad
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY
Engelbert Catherine M.
Transaction: 06/05/2026
BUY
Change
+4,545
Price
Not reported
Filing
06/08/2026
Type
BUY